Study #2025-0131
A phase I, multicenter study of CD4- directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CD4+ lymphoid hematological malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
CD4CAR
Description
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
T-cell Lymphoma, T-cell Leukemia
Study phase:
Phase I
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?